National medicine set a new record

Recently, pharmaceutical stocks have generally entered the stage of accelerating the rise, and its Chinese drug congruence (000028, stock bar) is a step-up attack, and yesterday it was a strong blocking of the trading board In the short term, the weak allocation market of pharmaceutical stocks is not over, and it is expected that Sinopharm is still expected to continue to set a new record Yesterday, Sinopharm rose all the way after a small opening, and the afternoon increase was further expanded The tail market closed the trading board strongly and closed at 51.49 yuan, a record high It should be said that the recent accelerated rise of Sinopharm is on the one hand based on the plate market of pharmaceutical stocks, and on the other hand is due to the market's high recognition of the company's products In the second half of 2013, the company actively carried out the certification of the new version of GMP Shenzhen Zhijun Guanlan base, Sinopharm holding Shenzhen traditional Chinese Medicine Co., Ltd and Sinopharm group Zhijun (Suzhou) Pharmaceutical Co., Ltd have passed the new version of GMP certification In addition, some of the company's production lines have also passed the EU certification, improving the international competitiveness Analysts said that at present, the market is generally optimistic about the company's sales in the domestic market and international mainstream markets such as Europe, so the institutions focus on such stocks with relatively certain growth In the short term, Sinopharm is still in an upward channel, and investors can continue to hold financing buying positions.